Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Dropped Thursday

By Joe Tenebruso – Updated May 22, 2020 at 8:29AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Skeptics are questioning the biotech's recent coronavirus vaccine-related announcements.

What happened

Shares of Moderna (MRNA -0.37%) fell nearly 9% on Thursday, continuing a downward trend that began soon after the biotechnology company's recent stock sale.

So what 

Moderna's stock soared on Monday after it released positive data from its phase 1 study for mRNA-1273, its coronavirus vaccine candidate. Moderna jumped 20% -- and gained approximately $5 billion in market value -- following the release of these preliminary results.

The biotech took advantage of the occasion to raise more than $1.25 billion in cash via a public share offering, which the company said it would use to manufacture its COVID-19 vaccine should it prove effective. 

Soon thereafter, analysts began to question whether the limited data Moderna provided warranted such a large upward move -- as well as the timing of its stock sale. 

A person in a business suit is inspecting a piece of paper with a magnifying glass.

After surging earlier in the week, shares of Moderna pulled back on Thursday as analysts parsed through the biotech's recent trial data. Image source: Getty Images.

Now what

While the timing of Moderna's stock sale understandably raised eyebrows, it's hard to fault the company for raising the money it will need to produce a vaccine that could -- should it prove safe and effective -- help to save millions of lives.

That said, Moderna's stock performance from this point forward will largely be determined by the outcome of its ongoing coronavirus vaccine studies. Investors will require much more clinical data than has been produced so far, which will hopefully continue to suggest that Moderna is making progress toward the successful development of a vaccine for COVID-19.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$125.15 (-0.37%) $0.47

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.